M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30
ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers.As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw.The approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile.Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE.The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region.Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025.Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.'
Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."
Source: Aletihad - Abu Dhabi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
10 hours ago
- Web Release
Fresh Del Monte Brings Its Iconic Pinkglow® Pineapple to the UAE, Redefining the Premium Fruit Market
Fresh Del Monte Produce Inc . (NYSE: FDP), a global leader in fresh produce and the world's only grower of the patented Pinkglow® pineapple, is expanding the global footprint of its premium pink-fleshed fruit with an exclusive launch in the United Arab Emirates. Beginning June 4, consumers in the UAE can purchase Pinkglow® pineapples only on talabat mart, the quick-commerce arm of talabat, the leading on-demand delivery platform in the MENA region. With its vibrant pink interior, delicate sweetness, and striking presentation, Pinkglow® pineapple has captivated global audiences since its debut. The pineapple is the result of over 16 years of research and development and is exclusively grown in Costa Rica and distributed by Fresh Del Monte, whose vertically integrated operations ensure rigorous quality, sustainability, and flavor standards from field to shelf. Until now, the Pinkglow® pineapple has only been available in select markets across North America and Asia, making its arrival in the UAE a major milestone in its global expansion. In the UAE, the Pinkglow® pineapple will be: Available only on talabat mart for six months. Sold in limited quantities weekly. Priced at AED 125 (approx. USD 34), positioning it as a premium fruit experience. Delivered in bespoke packaging, reinforcing its status as a giftable, must-try delicacy. 'This launch is a continuation of our mission to reimagine how the world experiences pineapples,' said Racha El Aawar, Fresh Del Monte's Director of Regional Marketing in the Middle East. 'We're not just selling fruit—we're curating indulgent, memorable moments rooted in decades of agricultural innovation. talabat mart's reach and cultural resonance in the UAE make them the perfect partner to introduce the Pinkglow® pineapple to consumers in the Middle East.' Alix Julien de Zelicourt, General Manager, talabat mart said, 'At talabat mart, we take pride in consistently unearthing unique and premium products for our customers; a true reflection of our pioneering spirit. The Pinkglow® pineapple celebrates this: bold, vibrant, and extraordinary. We're proud to be the only platform bringing this iconic fruit to customers in the UAE.' Since its debut, Pinkglow® pineapples have become a global phenomenon, embraced by celebrities, tastemakers, influencers, and event planners for their visually stunning pink flesh and vibrant aesthetic. Whether served at luxury brunches, styled on social feeds, or gifted as a statement piece, Pinkglow® pineapple delivers both flavor and flair. Today, Fresh Del Monte remains the unrivaled leader in the global pineapple category, offering proprietary varieties like Honeyglow® pineapples, Rubyglow® pineapples, Pinkglow® pineapples, and the DM Zero® pineapple—each designed to elevate taste, appearance, and appeal to different consumers. The company's vertically integrated model enables rapid innovation and quality control across the supply chain, responding to evolving consumer preferences with unmatched agility.
Zawya
a day ago
- Zawya
Brookfield Asset Management plans $10bln data centre for AI in Sweden
STOCKHOLM - Brookfield Asset Management (BAM) plans to invest up to 95 billion Swedish crowns ($9.91 billion) to build a data centre for artificial intelligence in Sweden, the Canadian company said in a statement on Wednesday. BAM said the site in the Swedish city of Strangnas west of Stockholm will create more than 1,000 permanent jobs and around 2,000 jobs during a 10-15 year construction process. "This investment represents one of Brookfield's largest AI investments in Europe and extends the partnership with the Swedish government, its public authorities, academia and businesses in the region," the company said in the statement. Swedish Prime Minister Ulf Kristersson welcomed the announcement, he said on social media X. U.S. tech group Nvidia last month announced that it will provide its latest generation AI data centre platform to a group of Swedish companies, including telecoms gear maker Ericsson and drug developer AstraZeneca. ($1 = 9.5845 Swedish crowns)
Gulf Today
2 days ago
- Gulf Today
Renowned Egyptian actress Samiha Ayoub passes away at 93
The renowned Egyptian actress Samiha Ayoub passed away on Tuesday, June 3, 2025, at the age of 93. Ayoub was one of the giants of Arab theatre, with a distinguished artistic career spanning from 1947 until her passing, encompassing theatre, cinema, and television. No official statement has been issued regarding the cause of her death. However, in early May, rumors circulated suggesting she was battling breast cancer. In a phone interview, Ayoub denied these rumors, stating: 'All these are false reports. I am in good health, and instead of spreading nice rumors, people spread bad ones.' She affirmed that her health was stable and denied any reports of suffering from tumors. Despite several media outlets reporting that she had breast cancer, Ayoub never officially confirmed the diagnosis. In previous remarks, she stated that she was in good health and continued to follow up with her doctor for treatment. She also expressed her eagerness to return to her audience with new and diverse roles. Speculation about her health intensified after she was recently seen with swelling in her hands, reportedly a result of lymphedema—a condition common among breast cancer patients. Lymphedema typically occurs following the removal of lymph nodes, leading to fluid retention and swelling in the affected limb. Ayoub was born on March 8, 1932, in the Shubra district of Cairo. She graduated from the Higher Institute of Dramatic Arts, where she was mentored by the renowned theatre director Zaki Tulaimat. He introduced her to the stage while she was still a student, casting her in the play Khedmet El-Malika (The Queen's Service), which marked the beginning of her artistic journey. Throughout her illustrious career, Ayoub starred in numerous plays, including Siket El-Salama, El-Sebnsa, El-Nadam, Phedra, El-Wazeer El-Aasheq, and El-Soltan El-Haer. She served as the director of the Modern Theatre in 1972 and later managed the National Theatre from 1975, holding the position for 14 years. Her theatrical repertoire included 170 plays, five of which she directed, including Maqalib Atia. Ayoub's legacy remains a cornerstone of Arab theatre and cinema, leaving behind an indelible mark on the artistic world.
